London's FTSE 100 declined on Monday, closing 0.20% in the red, amid concerns over the expiration of the interim US-Iran ceasefire and ahead of a busy week of UK economic data.
With discussions over peace and transit through the Strait of Hormuz at a standstill, US President Donald Trump warned Americans to brace for persistently high fuel prices. The US also explored new sanctions on Iran, while Israel attacked Lebanon over the weekend. Yet, Iran threatened that the waterway will remain blocked until the US admits defeat.
On the macro calendar, labor data is due Tuesday, July inflation print on Wednesday, the industrial trends report on Thursday, and consumer confidence, retail sales, and August PMI on Friday.
"We expect UK headline inflation to rise from 2.6% in June to 2.9% in July - 10 [basis points] above the [Bank of England's] forecast," BofA Global Research said. "The UK unemployment rate should fall to 4.8%, but private regular wage growth is likely to move a tad lower, too. We continue to see the central bank on hold in 2026, although risks are tilted to a hike later this year."
In corporate news, drugmaker AstraZeneca (AZN.L) gained 0.73% after separate phase 3 trials of the Tagrisso-Orpathys combination treatment and Enhertu showed improved progression-free survival of certain lung cancer patients. Meanwhile, the drugmaker terminated another phase 3 trial evaluating volrustomig in combination with chemotherapy to treat metastatic non-small cell lung cancer.
"This trial fail, while high risk, brings AZN pipeline risk back into focus following high profile Wainua PIII fail and recent high profile media speculation for a [Bristol Myers Squibb] merger. Investors have been consistently more cautious of AZN's bispecific strategy (this and PD1/TIGIT) and may further investor caution on strength of oncology pipeline into an oncology patent cliff (Lynparza 27E, Imfinzi 31E, Calquence & Tagrisso 32E)," BofA said in another note.
HSBC (HSBA.L) raised $6.75 billion from the issuance of three series of senior unsecured notes intended for listing on the New York Stock Exchange. The lender also issued SG$450 million in fixed-rate resettable notes on the London bourse's main market. The stock was 0.43% in the green at the session's close.
Deutsche Bank Research reduced Entain's (ENT.L) price target to 9.14 pounds sterling from 9.5 pounds, with a buy rating. "Entain reported 1H EBITDA of GBP479m (-2% yoy), 3% ahead of company-compiled consensus of GBP464m (DBe GBP452m). UK online revenue grew 13% (c/fx), ahead of peers which have recently reported. Australia (+13%) was the other standout region which has seen three consecutive quarters of market share gains. In total 1H online revenue +7%, at the top end of 5-7% FY guidance," analysts said. The sports betting and gaming group was down 0.29%.